Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Provocative Results for Immunotherapy in Advanced NSCLC: Dr. Joel Neal on Anti-PD-1
Author
Howard (Jack) West, MD

Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered several targeted therapy options that are still working their way through investigational work.  There were several promising agents reported as potential treatments for lung cancer, but perhaps none was more exciting than anti-PD-1 immunotherapy that was described by Dr. Julie Brahmer in a podcast from a few months ago.  She actually led and presented the work on anti-PD-1 in lung cancer at ASCO, but she wasn't able to share her exciting early results prior to ASCO.  Dr. Neal provides both some background and a summary of the results that were so encouraging to the lung cancer community.

Below you'll find the video and audio versions of the podcast, along with the transcript and figures.

Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Audio Podcast 

Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Figs

Dr. Neal ASCO 2012 LC Highlights Anti-PD-1 Transcript

So how encouraged are you by these results?  

We'll continue with other novel therapies presented at ASCO 2012 and summarized by Dr. Neal in our next podcast.  

In the meantime,

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on